Redhill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Decrease in Short Interest

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a large decrease in short interest in February. As of February 13th, there was short interest totaling 33,139 shares, a decrease of 47.1% from the January 29th total of 62,681 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average trading volume of 41,381 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 41,381 shares, the short-interest ratio is currently 0.8 days. Approximately 0.7% of the shares of the company are short sold.

Redhill Biopharma Trading Down 1.0%

NASDAQ RDHL opened at $0.97 on Monday. Redhill Biopharma has a 1-year low of $0.91 and a 1-year high of $3.60. The company has a market capitalization of $4.96 million, a price-to-earnings ratio of 0.00 and a beta of 4.91. The stock’s 50 day moving average is $1.15 and its two-hundred day moving average is $1.33.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Redhill Biopharma in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP bought a new stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma makes up approximately 0.3% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 19th largest holding. Yorkville Advisors Global LP owned about 7.57% of Redhill Biopharma as of its most recent filing with the SEC. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.